Table 2. A consolidated table showing the hospital course, comorbidities, concurrent treatment, maternal outcome.
ICU: intensive care unit; GDM: gestational diabetes mellitus
| Hospital course | Mean days (SD) |
| Days from the onset of COVID-19 symptoms to admission | 8.7 (3) |
| Day of starting tocilizumab following admission | 3.96 (3.47) |
| Duration of stay in the ICU | 12.26 (18.96) |
| Risk factor (n=28) | Number of patients (%) |
| Nil | 16 (57.14) |
| GDM | 9 (32.1) |
| Hypothyroid | 3 (10.7) |
| Concurrent treatment | Number of patients (%) |
| Steroid | 28 (100) |
| Kaletra | 3 (10.7) |
| Bioferon | 28 (100) |
| Remdesivir | 24 (85.7) |
| Antibiotics | 28 (100) |
| Plasma | 2 (7.1) |
| Follow-up at 28 days (n=28) | Number of patients (%) |
| Discharged | 25 (90%) |
| ICU | 2 (7.2%) |
| Mortality | 1 (3.6%) |
| Follow-up at 60 days (n=28) | Number of patients (%) |
| Discharged | 25 (90%) |
| ICU | 1 (3.6%) |
| Mortality | 2 (7.2%) |